Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-822

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-822 Category Tag

Product Details

Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efmitermant Alfa is a human follistatin fragment fused via a peptidyl linker to a human immunoglobulin G2 Fc fragment, dimer: it is used for the treatment of Charcot-Marie-Tooth disease

Products Name (INN Index)

Pre-Made Efmitermant Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP

INN Name

efmitermant alfa

Target

MSTN

Format

Fusion Protein

Derivation

Human

Species Reactivity

Human

CH1 Isotype

Fusion – [FST (follistatin)]2 – IGHG2 Fc (Fragment constant)

VD LC

Fusion – [FST (follistatin)]2 – IGHG2 Fc (Fragment constant)

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Acceleron?Pharma, Inc (Cambridge UK)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MSTN

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide